Moreover, innovative treatment approaches, such as utilizing anti-carcinoembryonic antigen (CEA) bispecific T-cells, have generated impressive responses in colorectal cancer, which is characterized by low MSI. This evidence concerns the gene CEACAM5 and colorectal cancer.